CHROMADERM
Chromaderm develops a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production.
Similar Organizations
Ion Biotechnology (USA), Inc.
Ion Biotechnology is developing drugs based on ionic metals which show promise against a range of cancers and infectious disease.
Sunol Molecular
A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.
Tilden Bio
Tilden Bio develops photosynthetic bioproducts including natural plant essential oils, cannabinoids, and biopharmaceutical proteins.
More informations about "Chromaderm"
Chromaderm - Crunchbase Company Profile & Funding
Organization. Chromaderm . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Chromaderm develops a topical inhibitor of melanin production …See details»
Chromaderm Company Profile 2024: Valuation, Investors
Chromaderm General Information Description. Developer of topical a topical inhibitor of melanin production intended to treat hyperpigmentation disorders. The company's inhibitor can be …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to …
Dec 21, 2021 Chromaderm’s drug candidate, ruboxistaurin (SM-030), is an inhibitor of PKC-beta, which Chromaderm’s co-founder Dr. Barbara Gilchrest demonstrated is required for …See details»
Chromaderm - Products, Competitors, Financials, Employees, …
About Chromaderm. Chromaderm is a clinical-stage biotechnology company. It provides treatments for Melasma and other skin hyperpigmentation disorders. It is based in Cambridge, …See details»
Chromaderm, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Chromaderm, Inc. with its drug pipeline, therapeutic area, technology platform, 10 clinical trials, Drug:Ruboxistaurin Mesilate Hydrate. ... The statistics for drugs in the Pipeline is the …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to …
Dec 21, 2021 DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised …See details»
DermBiont acquires Chromaderm - 2021-12-21 - Crunchbase
Dec 21, 2021 Chromaderm Chromaderm develops melanin production as therapy for skin brightening, melasma, and skin diseases associated with melanin production. Acquiring …See details»
DermBiont Acquires Chromaderm - - PracticalDermatology
Dec 21, 2021 Chromaderm’s drug candidate, ruboxistaurin (SM-030), is an inhibitor of PKC-beta, which Chromaderm’s co-founder Dr. Barbara Gilchrest demonstrated is required for …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to ...
May 15, 2023 BOSTON--(BUSINESS WIRE)-- DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes …See details»
DermBiont - Funding, Financials, Valuation & Investors - Crunchbase
Which types of acquisition does this organization make most frequently? Show . Acquiree Name . Announced Date . Price . Transaction Name . Chromaderm . Dec 21, 2021 — Chromaderm …See details»
DermBiont Raises $8M Series A to Treat the Root ... - Microbiome …
Jun 19, 2019 “DermBiont is building a world class research and development organization with deep and relevant experience to discover and develop first-in-class skin microbiome …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to …
Dec 21, 2021 Chromaderm’s drug candidate, ruboxistaurin (SM-030), is an inhibitor of PKC-beta, which Chromaderm’s co-founder Dr. Barbara Gilchrest demonstrated is required for …See details»
DermBiont Raises $28 Million and Acquires Chromaderm
Dec 23, 2021 DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in DevelopmentSee details»
Organization | Chromaderm, Inc.
Chromaderm, Inc. Report issue For profit Phase 3 Founded: Cambridge MA United States (2014)See details»
Chromaderm - Tech Stack, Apps, Patents & Trademarks
Chromaderm develops melanin production as therapy for skin brightening, melasma, and skin diseases associated with melanin production.See details»
DermBiont raises $28 million and aims to develop ruboxistaurin
Dec 21, 2021 Topical dermatology specialist DermBiont has raised $28 million in a series A financing, at the same time as acquiring clinical-stage biotech Chromaderm. The Boston, USA …See details»
Ruboxistaurin Mesilate Hydrate - Drug Targets, Indications, …
Eli Lilly had originally conducted a phase 3 trial of the drug, also known as ruboxistaurin, for diabetic retinopathy almost 20 years ago, before out-licensing the therapy to Chromaderm in …See details»
DermBiont Raises $28 Million and Acquires Chromaderm to
Dec 21, 2021 Chromaderm’s drug candidate, ruboxistaurin (SM-030), is an inhibitor of PKC-beta, which Chromaderm’s co-founder Dr. Barbara Gilchrest demonstrated is required for …See details»
Recursion reprioritizes, dumping rare disease asset while raking in ...
Oct 26, 2022 Eli Lilly had originally conducted a phase 3 trial of the drug, also known as ruboxistaurin, for diabetic retinopathy almost 20 years ago, before out-licensing the therapy to …See details»
7 Things that Changed Dermatology Practice - Chroma Dermatology
Reflections on 7 things that have changed dermatology practice in the last decadeSee details»